TY - JOUR
T1 - A novel cognitive-functional composite measure to detect changes in early Alzheimer's disease: Test–retest reliability and feasibility
AU - Jutten, Roos J.
AU - Harrison, John
AU - Lee Meeuw Kjoe, Philippe R.
AU - Opmeer, Esther M.
AU - Schoonenboom, Niki S. M.
AU - de Jong, Frank Jan
AU - Ritchie, Craig W.
AU - Scheltens, Philip
AU - Sikkes, Sietske A. M.
PY - 2018
Y1 - 2018
N2 - Introduction: To improve the detection of changes in Alzheimer's disease (AD), we designed the cognitive-functional composite (CFC). As a first validation step, we investigated its test–retest reliability and feasibility of use. Methods: We performed a test–retest study with 2–3 weeks between assessments, including patients with mild cognitive impairment (MCI) or mild AD dementia and cognitively healthy participants. We calculated intraclass correlation coefficients (ICCs) type absolute agreement for all CFC measures and compared baseline and retest scores using paired-samples t-tests. We evaluated feasibility by interviewing participants. Results: Forty-three patients (40% female, mean age = 69.9) and 30 controls (50% female, mean age = 65) were included. Subtest intraclass correlation coefficients ranged from.70 to.96. We found negligible improvements after retesting on only two subtests. Overall, patients perceived the administration of the CFC as feasible. Discussion: The CFC is a stable and feasible measure in MCI and mild AD dementia, and thereby meets important quality metrics for clinically meaningful outcome measures.
AB - Introduction: To improve the detection of changes in Alzheimer's disease (AD), we designed the cognitive-functional composite (CFC). As a first validation step, we investigated its test–retest reliability and feasibility of use. Methods: We performed a test–retest study with 2–3 weeks between assessments, including patients with mild cognitive impairment (MCI) or mild AD dementia and cognitively healthy participants. We calculated intraclass correlation coefficients (ICCs) type absolute agreement for all CFC measures and compared baseline and retest scores using paired-samples t-tests. We evaluated feasibility by interviewing participants. Results: Forty-three patients (40% female, mean age = 69.9) and 30 controls (50% female, mean age = 65) were included. Subtest intraclass correlation coefficients ranged from.70 to.96. We found negligible improvements after retesting on only two subtests. Overall, patients perceived the administration of the CFC as feasible. Discussion: The CFC is a stable and feasible measure in MCI and mild AD dementia, and thereby meets important quality metrics for clinically meaningful outcome measures.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85041481072&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/29780863
U2 - 10.1016/j.dadm.2017.12.002
DO - 10.1016/j.dadm.2017.12.002
M3 - Article
C2 - 29780863
VL - 10
SP - 153
EP - 160
JO - Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
JF - Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
SN - 2352-8729
ER -